Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1976 1
1977 1
1979 1
1984 1
1985 1
1988 1
1989 1
1993 1
1994 1
1995 1
1997 2
1998 1
2000 1
2001 1
2004 4
2005 1
2006 4
2007 2
2008 3
2009 5
2010 8
2011 6
2012 3
2013 10
2014 8
2015 8
2016 4
2017 10
2018 5
2019 4
2020 6
2021 3
2022 11
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Results by year

Filters applied: . Clear all
Page 1
Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium.
Bangalore Krishna K, Fuqua JS, Rogol AD, Klein KO, Popovic J, Houk CP, Charmandari E, Lee PA, Freire AV, Ropelato MG, Yazid Jalaludin M, Mbogo J, Kanaka-Gantenbein C, Luo X, Eugster EA, Klein KO, Vogiatzi MG, Reifschneider K, Bamba V, Garcia Rudaz C, Kaplowitz P, Backeljauw P, Allen DB, Palmert MR, Harrington J, Guerra-Junior G, Stanley T, Torres Tamayo M, Miranda Lora AL, Bajpai A, Silverman LA, Miller BS, Dayal A, Horikawa R, Oberfield S, Rogol AD, Tajima T, Popovic J, Witchel SF, Rosenthal SM, Finlayson C, Hannema SE, Castilla-Peon MF, Mericq V, Medina Bravo PG. Bangalore Krishna K, et al. Horm Res Paediatr. 2019;91(6):357-372. doi: 10.1159/000501336. Epub 2019 Jul 18. Horm Res Paediatr. 2019. PMID: 31319416 Free article. Review.
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Kasliwal R, Jaitly S, Campbell N, Ho PR, Licata S; Tysabri Observational Program (TOP) Investigators. Butzkueven H, et al. J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660-668. doi: 10.1136/jnnp-2019-322326. Epub 2020 Mar 31. J Neurol Neurosurg Psychiatry. 2020. PMID: 32234967 Free PMC article.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency.
Reifschneider A, Robinson S, van Lengerich B, Gnörich J, Logan T, Heindl S, Vogt MA, Weidinger E, Riedl L, Wind K, Zatcepin A, Pesämaa I, Haberl S, Nuscher B, Kleinberger G, Klimmt J, Götzl JK, Liesz A, Bürger K, Brendel M, Levin J, Diehl-Schmid J, Suh J, Di Paolo G, Lewcock JW, Monroe KM, Paquet D, Capell A, Haass C. Reifschneider A, et al. EMBO J. 2022 Feb 15;41(4):e109108. doi: 10.15252/embj.2021109108. Epub 2022 Jan 12. EMBO J. 2022. PMID: 35019161 Free PMC article.
Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial.
Maniatis AK, Nadgir U, Saenger P, Reifschneider KL, Abuzzahab J, Deeb L, Fox LA, Woods KA, Song W, Mao M, Chessler SD, Komirenko AS, Shu AD, Casella SJ, Thornton PS. Maniatis AK, et al. Horm Res Paediatr. 2022;95(3):233-243. doi: 10.1159/000524003. Epub 2022 Mar 9. Horm Res Paediatr. 2022. PMID: 35263755 Free PMC article. Clinical Trial.
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D; ALLAY-LID I and ALLAY-LID II study groups. Rascol O, et al. Parkinsonism Relat Disord. 2022 Mar;96:65-73. doi: 10.1016/j.parkreldis.2022.01.022. Epub 2022 Feb 8. Parkinsonism Relat Disord. 2022. PMID: 35227940 Free article. Clinical Trial.
Faculty achievement tracking tool.
Pettus S, Reifschneider E, Burruss N. Pettus S, et al. J Nurs Educ. 2009 Mar;48(3):161-4. doi: 10.3928/01484834-20090301-05. J Nurs Educ. 2009. PMID: 19297967 Review.
116 results